IM-250 explained

IM-250 is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.[3]

Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.[4]

See also

Notes and References

  1. Gege . Christian . Bravo . Fernando J. . Uhlig . Nadja . Hagmaier . Timo . Schmachtenberg . Rosanne . Elis . Julia . Burger-Kentischer . Anke . Finkelmeier . Doris . Hamprecht . Klaus . Grunwald . Thomas . Bernstein . David I. . Kleymann . Gerald . A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections . Science Translational Medicine . 16 June 2021 . 13 . 598 . 10.1126/scitranslmed.abf8668. 34135112 .
  2. Web site: Drug Candidate Shows 'Potent Anti-Herpes Activity' . 17 June 2021 .
  3. Web site: Small molecule fights active and latent herpes infections in rodents .
  4. Lücking . Ulrich . New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective . Chemistry – A European Journal . 7 October 2022 . 28 . 56 . e202201993 . 10.1002/chem.202201993. 35789054.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "IM-250".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.